Chikungunya Outbreak in Italy: What You Need to Know
"A new cluster of autochthonous chikungunya virus has been identified in Italy's Latium region, raising concerns about the spread of this mosquito-borne disease. Here's what you need to know to stay informed and protected."
Chikungunya virus (CHIKV) is back in the news with a localized transmission confirmed in the Latium region of Italy. Two related clusters have emerged in the cities of Anzio and Rome, marking the second known autochthonous outbreak of CHIKV in Italy. The first occurred in 2007 in the Emilia Romagna region.
Between these two Italian epidemics, other transmissions were reported in France in 2010, 2014, and 2017, highlighting the ongoing concern about this infection. The primary culprit? The Aedes albopictus mosquito, which has established itself across the Mediterranean basin and beyond.
Currently, Aedes albopictus is assumed to be the vector in the Italian outbreak, as Aedes aegypti mosquitoes are not present in the country. The Laboratory of Virology of Lazzaro Spallanzani National Institute for Infectious Disease (INMI) in Rome, is responsible for CHIKV diagnosis and surveillance in the Latium region.
Global Scale and Health Impact
The European Centre for Disease Prevention and Control reported that, since the start of 2026 and as of 5 August, 219,522 chikungunya virus disease cases and 81 associated deaths had been detected in 25 countries, excluding EU/EEA countries and territories. Chikungunya virus is primarily transmitted by Aedes mosquitoes and commonly causes fever, rash, and debilitating joint pain. Some patients develop long-term joint pain and disabilities, although the overall fatality rate is low and severe disease is more likely in vulnerable populations.
Diagnosis Depends on Timing
Diagnostic strategies for chikungunya vary across stages of infection, and accurate, timely diagnosis remains challenging. Laboratory diagnosis depends on when a sample is collected relative to symptom onset, creating an important limitation for testing. Medscape reports that testing is not routinely available at commercial laboratories and recommends that clinicians contact a state health department or the CDC Arboviral Diseases Branch for guidance on sample submission.
From East Africa to Global Spread
Chikungunya was first characterized in a human outbreak in East Africa in 1952, near the boundary of Tanzania and Mozambique. The virus has a history of moving from ancestral enzootic and sylvatic cycles into urban transmission cycles. Since 2004, its reemergence has produced millions of cases of severe, debilitating, and often chronic arthralgia across five continents, including its spread to the Americas beginning in 2013.
Decoding the Chikungunya Outbreak: Key Facts & Prevention
CHIKV diagnosis relies on detecting the viral genome via real-time reverse transcription PCR (RT-PCR) and identifying virus-specific antibodies through serologic tests. Scientists analyze endpoint PCR amplicons from selected patients to confirm the virus's identity, verified by real-time RT-PCR, and attempt virus isolation whenever possible.
- Symptoms: Fever, joint pain, headache, muscle pain, joint swelling, or rash.
- Prevention: Use insect repellent, wear long sleeves and pants, and control mosquitoes indoors and outdoors.
- Seek Medical Attention: If you develop symptoms of chikungunya, see your doctor.
Italy as a European Warning
Chikungunya spread beyond its original tropical locations in Africa and the Indian subcontinent, becoming an emerging concern in temperate Europe and the Americas. In continental Europe, autochthonous outbreaks were reported in Italy in 2007 and in France in 2010, 2014, and 2017. A 2017 outbreak in central Italy later evolved into a secondary cluster in southern Italy, providing evidence that the disease could emerge in new areas.
Small Towns, Wider Risk
A comparative analysis of the 2007 and 2017 Italian outbreaks found that both began in small towns. Cases were also detected in nearby larger cities, although transmission there was limited to small clusters. Molecular studies emphasized that further research was needed to determine how genetic signatures affected viral fitness in local mosquito vectors and to clarify the extent of human transmission cycles.
Confirmed and Probable Cases
A study of local transmission in Rome and the Lazio region analyzed 402 remaining cases. Of these, 200 cases, or 49.8%, were classified as confirmed. The other 202 cases, or 50.2%, were classified as probable, illustrating how outbreak assessments may include both laboratory-confirmed and epidemiologically supported cases.
Genetic Insights and Future Research
Genetic sequencing reveals the virus in the Latium outbreak belongs to the East/Central/South African (ECSA) clade, similar to the 2007 Italy outbreak. However, the current sequences fall into a separate branch, suggesting a more recent origin. Unlike the 2007 outbreak, the E1 sequences from the ongoing outbreak lack the A226V mutation. Further research will explore the implications of this and other genetic signatures.
An Underestimated Global Burden
Chikungunya is an emerging global public health threat caused by a mosquito-borne alphavirus primarily transmitted by Aedes aegypti and Aedes albopictus. Research on its global health and economic burden notes that existing estimates remain limited and may underestimate the true impact. Experts also report that outbreaks can intensify rapidly, creating a substantial endemic burden in tropical and subtropical areas and risks for travelers.
Climate and Expanding Transmission
A 2026 scoping study describes climate change as accelerating the circulation of chikungunya virus. It identifies risks both for endemic areas and for immunologically naive temperate regions, while examining climatic drivers, future transmission projections, and adaptation strategies. A separate review reports that chikungunya has expanded to more than 100 countries and highlights the 2025 epidemic in Réunion Island and local transmission in Foshan City.
Pain Beyond the Outbreak
Chikungunya typically causes sudden-onset high fever, severe arthralgia, myalgia, headache, rash, and fatigue. Although life-threatening complications and fatalities are rare, arthritis-like pain can persist and affect people beyond the acute illness. Research is also examining why the severity of mosquito-borne disease outbreaks varies, using chikungunya as a case study, while burden studies warn that health and economic impacts may be underestimated.